(Total Views: 1812)
Posted On: 03/06/2022 1:58:48 PM
Post# of 4861
Title: Con Mucho Gusto
Subtitle: VitaminCBD™ goes to Peru.
Kim McCarthy of The Pipeline Strategies has just taken VitaminCBD™ with her to Peru to meet with a number of interested parties. She will meet with the only state-approved dispensary for all non-THC products. We are most excited to have been selected to travel with her to Peru. The acceptance of the cannabinoids is nothing new for countries outside of the United States. Much of the research that helped to develop the new cannabinoid system and the benefits of CBD and the other cannabinoids have been done outside of the United States.
As America went into a prohibition centered around the cannabis plant dating back to 1937, all incentives to grow hemp were abolished. Cannabis had to overcome the hemp plant’s criminalization that made the plant as a controlled narcotic per the Controlled Substances Act (CSA) in 1970 under the Nixon administration and designated as a Schedule one drug.
What is a Schedule one drug: Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Health and Human Services (HHS) of the United States government has held a patent on CBD since 2003. In 1999, four NIH researchers applied for a patent because they found that CBD was neuroprotective, neural proliferative and a great antioxidant to fight oxidative stress and free radicals in the brain. This 1999 patent request was granted as Patent US6630507B1 by the United States Patent Office (USPO). This is how the abstract of that patent reads from July 2003: Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This newfound property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory, and autoimmune diseases.
The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Non psychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.
Please re-read this summary 6 times so you can commit it to memory. We just got word from Kim that VitaminCBD™ was warmly received and Peru will look at the procedures necessary to take this American made product formulated by a long-standing research physician, Eric I Mitchell, MD, which is an organic, third-party tested hemp product and export it to Peru.
To be able to reach the international market is another pinnacle that Vitamin CBD™ looks forward to earning. A big shout out to The Pipeline Strategies for not only picking our product but sharing our educational push to teach the public about the Endocannabinoid System (ECS).
Authored by
Eric I. Mitchell MD FACPE
Website: https://dailyvitamincbd.com/
Phone: 1-207-852-4396
As important, Doctor Mitchell now is offering 2Path+
2Path+ is the first and only product specifically formulated to combat Covid-19. 2Path+ acts as a preventative that inhibits the attachment of Covid-19 to the spike proteins that cause the various types of Covid. In addition, Mitchell sells a product called 2Path MD which contains a small percentage of THC intended to enhance the entourage effect of CBD products. The MD stands for micro dosing and not for medical doctor.
Subtitle: VitaminCBD™ goes to Peru.
Kim McCarthy of The Pipeline Strategies has just taken VitaminCBD™ with her to Peru to meet with a number of interested parties. She will meet with the only state-approved dispensary for all non-THC products. We are most excited to have been selected to travel with her to Peru. The acceptance of the cannabinoids is nothing new for countries outside of the United States. Much of the research that helped to develop the new cannabinoid system and the benefits of CBD and the other cannabinoids have been done outside of the United States.
As America went into a prohibition centered around the cannabis plant dating back to 1937, all incentives to grow hemp were abolished. Cannabis had to overcome the hemp plant’s criminalization that made the plant as a controlled narcotic per the Controlled Substances Act (CSA) in 1970 under the Nixon administration and designated as a Schedule one drug.
What is a Schedule one drug: Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Health and Human Services (HHS) of the United States government has held a patent on CBD since 2003. In 1999, four NIH researchers applied for a patent because they found that CBD was neuroprotective, neural proliferative and a great antioxidant to fight oxidative stress and free radicals in the brain. This 1999 patent request was granted as Patent US6630507B1 by the United States Patent Office (USPO). This is how the abstract of that patent reads from July 2003: Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This newfound property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory, and autoimmune diseases.
The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Non psychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.
Please re-read this summary 6 times so you can commit it to memory. We just got word from Kim that VitaminCBD™ was warmly received and Peru will look at the procedures necessary to take this American made product formulated by a long-standing research physician, Eric I Mitchell, MD, which is an organic, third-party tested hemp product and export it to Peru.
To be able to reach the international market is another pinnacle that Vitamin CBD™ looks forward to earning. A big shout out to The Pipeline Strategies for not only picking our product but sharing our educational push to teach the public about the Endocannabinoid System (ECS).
Authored by
Eric I. Mitchell MD FACPE
Website: https://dailyvitamincbd.com/
Phone: 1-207-852-4396
As important, Doctor Mitchell now is offering 2Path+
2Path+ is the first and only product specifically formulated to combat Covid-19. 2Path+ acts as a preventative that inhibits the attachment of Covid-19 to the spike proteins that cause the various types of Covid. In addition, Mitchell sells a product called 2Path MD which contains a small percentage of THC intended to enhance the entourage effect of CBD products. The MD stands for micro dosing and not for medical doctor.
(1)
(0)Scroll down for more posts ▼
